Abstract 189P
Background
Malignant tumors are sophisticated, organized ecosystems in addition to collections of cancer cells. It has long been established that the formation, recurrence, and metastasis of cancers are all tightly correlated with their immune components. However, the impact of the tumor microenvironment in soft tissue sarcoma (STS) remains mainly unclear. Studying how the immunological microenvironment affects the clinical presentation and prognosis of soft tissue sarcomas is the objective.
Methods
Retrospective research was conducted on 168 soft tissue sarcoma patients who received care at the Republican specialized Scientific and practical Medical Center of Oncology and Radiology of Uzbekistan. Through immunohistochemistry analyses of CD3, CD4, CD8, CD20, and CD68, lymphocyte subpopulations that infiltrate tumours and their subpopulations were investigated.
Results
In the immunological microenvironment, CD 68+ macrophages and CD 3+ T cells were the most prevalent cell types. There was a substantial positive correlation between CD 68 expression and the probability of local recurrence (p = 0.014) in a multivariate analysis employing the Fine & Gray risk regression model with death as a competing event, independent of age, resection margins, and the presence of B cells. Furthermore, B cell abundance was significantly lower (p = 0.013) and macrophage abundance was much higher in patients older than middle age. Regarding histological subtypes, undifferentiated pleomorphic sarcoma and myxofibrosarcoma were more frequently found to have these cells, which had a high total number of tumor-infiltrating lymphocytes in general and macrophages in particular.
Conclusions
The significant number of CD 68 macrophages in soft tissue sarcomas and their detrimental effect on the prognosis for local recurrence are both confirmed by this investigation.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display